Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: update

Precision oncology is now the evidence-based standard of care for the management of many advanced non-small cell lung cancers (NSCLC). Notably, new molecular profiling technologies have permitted dynamic growth in the identification of actionable driver oncogenes including RET rearrangements. RET o...

Full description

Bibliographic Details
Main Author: Luis Mendoza
Format: Article
Language:English
Published: PAGEPress Publications 2018-07-01
Series:Oncology Reviews
Subjects:
Online Access:https://www.oncologyreviews.org/index.php/or/article/view/352